pubmed.ncbi.nlm.nih.gov

GHB (gamma-hydroxybutyrate) carrier-mediated transport across the blood-brain barrier - PubMed

GHB (gamma-hydroxybutyrate) carrier-mediated transport across the blood-brain barrier

Indranil Bhattacharya et al. J Pharmacol Exp Ther. 2004 Oct.

Abstract

gamma-Hydroxybutyrate (sodium oxybate, GHB) is an approved therapeutic agent for cataplexy with narcolepsy. GHB is widely abused as an anabolic agent, euphoriant, and date rape drug. Recreational abuse or overdose of GHB (or its precursors gamma-butyrolactone or 1,4-butanediol) results in dose-dependent central nervous system (CNS) effects (respiratory depression, unconsciousness, coma, and death) as well as tolerance and withdrawal. An understanding of the CNS transport mechanisms of GHB may provide insight into overdose treatment approaches. The hypothesis that GHB undergoes carrier-mediated transport across the BBB was tested using a rat in situ brain perfusion technique. Various pharmacological agents were used to probe the pharmacological characteristics of the transporter. GHB exhibited carrier-mediated transport across the BBB consistent with a high-capacity, low-affinity transporter; averaged brain region parameters were V(max) = 709 +/- 214 nmol/min/g, K(m) = 11.0 +/- 3.56 mM, and CL(ns) = 0.019 +/- 0.003 cm(3)/min/g. Short-chain monocarboxylic acids (pyruvic, lactic, and beta-hydroxybutyric), medium-chain fatty acids (hexanoic and valproic), and organic anions (probenecid, benzoic, salicylic, and alpha-cyano-4-hydroxycinnamic acid) significantly inhibited GHB influx by 35 to 90%. Dicarboxylic acids (succinic and glutaric) and gamma-aminobutyric acid did not inhibit GHB BBB transport. Mutual inhibition was observed between GHB and benzoic acid, a well known substrate of the monocarboxylate transporter MCT1. These results are suggestive of GHB crossing the BBB via an MCT isoform. These novel findings of GHB BBB transport suggest potential therapeutic approaches in the treatment of GHB overdoses. We are currently conducting "proof-of-concept" studies involving the use of GHB brain transport inhibitors during GHB toxicity.

PubMed Disclaimer

Cited by

Role of monocarboxylate transporters in drug delivery to the brain.
Vijay N, Morris ME. Vijay N, et al. Curr Pharm Des. 2014;20(10):1487-98. doi: 10.2174/13816128113199990462. Curr Pharm Des. 2014. PMID: 23789956 Free PMC article. Review.
Potential Therapeutic Effects of Short-Chain Fatty Acids on Chronic Pain.
Tang Y, Du J, Wu H, Wang M, Liu S, Tao F. Tang Y, et al. Curr Neuropharmacol. 2024;22(2):191-203. doi: 10.2174/1570159X20666220927092016. Curr Neuropharmacol. 2024. PMID: 36173071 Free PMC article. Review.
γ-Hydroxybutyrate blood/plasma partitioning: effect of physiologic pH on transport by monocarboxylate transporters.
Morse BL, Felmlee MA, Morris ME. Morse BL, et al. Drug Metab Dispos. 2012 Jan;40(1):64-9. doi: 10.1124/dmd.111.041285. Epub 2011 Oct 5. Drug Metab Dispos. 2012. PMID: 21976619 Free PMC article.
Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid.
Morris ME, Felmlee MA. Morris ME, et al. AAPS J. 2008 Jun;10(2):311-21. doi: 10.1208/s12248-008-9035-6. Epub 2008 Jun 4. AAPS J. 2008. PMID: 18523892 Free PMC article. Review.
Alterations in neuronal transport but not blood-brain barrier transport are observed during gamma-hydroxybutyrate (GHB) sedative/hypnotic tolerance.
Bhattacharya I, Raybon JJ, Boje KM. Bhattacharya I, et al. Pharm Res. 2006 Sep;23(9):2067-77. doi: 10.1007/s11095-006-9066-6. Epub 2006 Aug 10. Pharm Res. 2006. PMID: 16952000

GHB (gamma-hydroxybutyrate) carrier-mediated transport across the blood-brain barrier - PubMed